It was an absolute pleasure to speak with Dr Kenneth Cusi (University of Florida, Gainesville, FL, USA) about the novel compound PXL770 and the results of the STAMP-NAFLD phase 2 trial investigating its potential in NASH.
His abstract entitled ‘Human proof-of-concept in non-alcoholic liver disease (NAFLD) patients with PXL770, a novel first-in-class direct AMP-kinase activator — STAMP-NAFLD Phase 2a trial’ was presented at the International Liver Congress (ILC) 2021, 23-26 June.
Questions
- PXL770 is a novel drug, could you tell us a little about its mechanism of action and the rationale for its potential use in metabolic disorders, such as NASH? (0:15)
- Could you give us a brief overview of the STAMP-NAFLD Phase 2a trial, including the overall aim, design and outcome measures? (1:38)
- What has the study demonstrated in terms of clinical efficacy and safety? (2:25)
- On the basis of these findings, do you think that PXL770 offers a promising therapeutic approach for NASH, and if so, which patients could see the largest benefit? (4:04)
Disclosures: K.C. has received research support towards the University of Florida as principal investigator from the National Institute of Health (NIH), Cirius, Echosens, Inventiva, Novartis, Novo Nordisk, Poxel, and Zydus. K.C. is also a consultant for Allergan, Altimmune, Arrowhead, AstraZeneca, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Fractyl, Hanmi, Genentech, Gilead, Intercept, Janssen, Pfizer, Prosciento, Madrigal, and Novo Nordisk.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
